---
figid: PMC6607964__fonc-09-00547-g0006
figtitle: Snapshot of trastuzumab resistance pathway
organisms:
- Bos taurus
- Oryctolagus cuniculus
- Homo sapiens
- Rattus norvegicus
- clinical samples
pmcid: PMC6607964
filename: fonc-09-00547-g0006.jpg
figlink: /pmc/articles/PMC6607964/figure/F6/
number: F6
caption: Snapshot of trastuzumab resistance pathway. Model of trastuzumab resistance
  acquisition in BT474 Her2+ breast cancer cell line due to ANKRD44 silencing. (A)
  In sensitive BT474 cells (shCTRL) without ANKRD44 silencing, trastuzumab blocks
  the downstream PI3K/Akt pathway (black dotted arrows) and prevents cell growth.
  (B) Thanks to ANKRD44 silencing BT474 cells (shANK) become partially resistant to
  the treatment due to an up-regulation of TAK1/Akt proteins which constitutively
  activate NF-kβ p65 subunit and leads to its nuclear accumulation (blue arrows).
  The nuclear p65 subunit activates the expression of target pro-inflammatory genes,
  survival genes and cell cycle regulators. Moreover, the TAK/Akt pathway activates
  mTORC1 complex which mediates cell proliferation and simultaneously increase glycolysis
  rate through an overexpression of Lactate dehydrogenase Beta protein (LDHB).
papertitle: 'ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in
  Her2-Like Breast Cancer.'
reftext: Marco La Ferla, et al. Front Oncol. 2019;9:547.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9783764
figid_alias: PMC6607964__F6
figtype: Figure
organisms_ner:
- Homo sapiens
- Rattus norvegicus
- Bos taurus
- Oryctolagus cuniculus
redirect_from: /figures/PMC6607964__F6
ndex: bdebed06-deba-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6607964__fonc-09-00547-g0006.html
  '@type': Dataset
  description: Snapshot of trastuzumab resistance pathway. Model of trastuzumab resistance
    acquisition in BT474 Her2+ breast cancer cell line due to ANKRD44 silencing. (A)
    In sensitive BT474 cells (shCTRL) without ANKRD44 silencing, trastuzumab blocks
    the downstream PI3K/Akt pathway (black dotted arrows) and prevents cell growth.
    (B) Thanks to ANKRD44 silencing BT474 cells (shANK) become partially resistant
    to the treatment due to an up-regulation of TAK1/Akt proteins which constitutively
    activate NF-kβ p65 subunit and leads to its nuclear accumulation (blue arrows).
    The nuclear p65 subunit activates the expression of target pro-inflammatory genes,
    survival genes and cell cycle regulators. Moreover, the TAK/Akt pathway activates
    mTORC1 complex which mediates cell proliferation and simultaneously increase glycolysis
    rate through an overexpression of Lactate dehydrogenase Beta protein (LDHB).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - SHANK2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ANKRD44
  - PPP6C
  - SRGN
  - AKT1
  - AKT2
  - AKT3
  - LDHB
  - NFKB1
  - Erbb2
  - Pik3cg
  - Ankrd44
  - Akt1
  - Ldhb
  - Nfkb1
---
